BACKGROUND: Tetrathiomolybdate (TM) is a novel anticancer and anti-angiogenic agent, which acts through copper chelation and NF-kappaB inhibition. OBJECTIVE: This review summarizes the scientific rationale for the use of TM as an anticancer agent in human studies. METHODS: A systematic review of the literature was conducted for the use of TM in cancer including preclinical, animal and human studies. The results of this search are summarized in this review. RESULTS/ CONCLUSIONS: Copper chelation using TM has demonstrated efficacy in preclinical and animal models as an alternative and novel anti-angiogenic agent. Phase I and II clinical trials conducted in solid tumors using TM have demonstrated efficacy with favorable toxicity profile. The use of copper lowering as an anti-angiogenic strategy in the cancer chemopreventative setting remains to be investigated.
BACKGROUND:Tetrathiomolybdate (TM) is a novel anticancer and anti-angiogenic agent, which acts through copper chelation and NF-kappaB inhibition. OBJECTIVE: This review summarizes the scientific rationale for the use of TM as an anticancer agent in human studies. METHODS: A systematic review of the literature was conducted for the use of TM in cancer including preclinical, animal and human studies. The results of this search are summarized in this review. RESULTS/ CONCLUSIONS:Copper chelation using TM has demonstrated efficacy in preclinical and animal models as an alternative and novel anti-angiogenic agent. Phase I and II clinical trials conducted in solid tumors using TM have demonstrated efficacy with favorable toxicity profile. The use of copper lowering as an anti-angiogenic strategy in the cancer chemopreventative setting remains to be investigated.
Authors: Michelle L Turski; Donita C Brady; Hyung J Kim; Byung-Eun Kim; Yasuhiro Nose; Christopher M Counter; Dennis R Winge; Dennis J Thiele Journal: Mol Cell Biol Date: 2012-01-30 Impact factor: 4.272
Authors: Katherine M Aird; Jennifer L Allensworth; Ines Batinic-Haberle; H Kim Lyerly; Mark W Dewhirst; Gayathri R Devi Journal: Breast Cancer Res Treat Date: 2011-05-11 Impact factor: 4.872
Authors: Melissa Y Lucero; Yuqi Tang; Chloe J Zhang; Shengzhang Su; Joseph A Forzano; Valeria Garcia; Xin Huang; David Moreno; Jefferson Chan Journal: Proc Natl Acad Sci U S A Date: 2021-09-07 Impact factor: 11.205